Thursday, June 5, 2014

Hot Sliver Stocks To Buy For 2015

Hot Sliver Stocks To Buy For 2015: Takeda Pharmaceutical Co Ltd (TKPHF.PK)

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. Advisors' Opinion:
  • [By Markus Aarnio]

    Companies working on chemically synthesized siRNAs include Merck (MRK), through its subsidiary Sirna Therapeutics, Inc., Novartis (NVS), Takeda (TKPHF.PK), Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando, Quark, Silence Therapeutics plc, Tekmira (TKMR), Sylentis and Dicerna Pharmaceuticals, Inc.

  • [By Alpha Exposure]

    The most recent Affymax article states that Takeda withdrew from consideration for European approval "because they were doing the "root cause analysis" they would not be able to complete the investigation because it was still in process and "ongoing" despite the fact that severe reactions were not present at the time of the clinical trials." However, there is no evidence to support this conclusion. The truth is that we showed you an excerpt directly from the Committee for Medicinal Products for Human Use that stated the CHMP "was of the provisional opinion that Omontys could not have been approved" due to "study results indicating that Omontys ma! y increase the risk of death or heart and circulatory problems." It is clear that the EU application was withdrawn because Takeda (TKPHF.PK) could not get Omontys approved due to its safety profile.

  • source from Top Stocks For 2015:http://www.topstocksblog.com/hot-sliver-stocks-to-buy-for-2015.html

No comments:

Post a Comment